Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Neuroone Medical Technologies (NMTC) Accumulated Depreciation & Amortization (2020 - 2025)

Neuroone Medical Technologies' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $858768.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 38.73% year-over-year to $858768.0; the TTM value through Dec 2025 reached $858768.0, up 38.73%, while the annual FY2025 figure was $798823.0, 42.78% up from the prior year.
  • Accumulated Depreciation & Amortization reached $858768.0 in Q4 2025 per NMTC's latest filing, up from $798823.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $540.0 billion in Q3 2022 to a low of $58492.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $27.0 billion, with a median of $361523.0 recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 599604180.19% in 2022, then crashed 100.0% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $109634.0 in 2021, then surged by 97.63% to $216667.0 in 2022, then skyrocketed by 79.11% to $388062.0 in 2023, then skyrocketed by 59.51% to $619008.0 in 2024, then skyrocketed by 38.73% to $858768.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Accumulated Depreciation & Amortization are $858768.0 (Q4 2025), $798823.0 (Q3 2025), and $740078.0 (Q2 2025).